PCR Journal Club

To further investigate the treatment effects of ticagrelor monotherapy compared with ticagrelor plus aspirin in a contemporary HBR population, a pre-specified analysis of the TWILIGHT trial, TWILIGHT-HBR, was conducted by using the Academic Research Consortium (ARC) criteria for HBR.

The purpose of the present investigation was to revisit all stent expansion indexes to identify the best predictor of 2-year percutaneous coronary intervention (PCI) lesion-specific outcome measures (i.e. clinically-driven target lesion revascularization [TLR] or definite stent thrombosis) using the ADAPT-DES IVUS substudy cohort.

This investigator-initiated randomised, open-label, multicentre trial compares FFR versus angiography guided strategies for treating non-culprit lesions in patients presenting with STEMI and multivessel coronary artery disease. The results of this study were released during ACC.21.

The PIONEER III trial aims to assess the effectiveness and safety of the biodegradable-polymer sirolimus-eluting Supreme stent compared to durable-polymer everolimus-eluting stent (Xience or Promus), completely releasing the drug by 120 days.

The objective of this analysis was to prospectively investigate the clinical impact of post-PCI FFR values on long-term clinical outcomes.

In this large cohort, there was no evidence of increased long-term mortality following treatment with drug-coated devices. Read the review to find out more.